Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Trypsin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Trypsin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-003154-80 Sponsor Protocol Number: 2020CLI Start Date*: 2020-12-08
    Sponsor Name:Mucos Pharma GmbH & Co. KG
    Full Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment with Bromelain, Trypsin and Rutoside versus Placebo in Subjects wi...
    Medical condition: Subjects suffering from knee Osteoarthitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031161 Osteoarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014286-20 Sponsor Protocol Number: AGTC-AAT-002 Start Date*: 2010-12-21
    Sponsor Name:Applied Genetic Technologies Corporation
    Full Title: A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency
    Medical condition: Alpha 1 antitrypsin deficiency.This is an inherited, genetic condition characterized by reduced serum levels of alpha-1 antitrypsin (AAT) which increases the risk of developing emphysema and liver ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005003-40 Sponsor Protocol Number: BTS651/12 Start Date*: 2013-01-21
    Sponsor Name:MUCOS Pharma GmbH & Co. KG
    Full Title: Effects of Wobenzym® plus in healthy, sportive people after eccentric exercise - a randomized, two-stage, double-blind, placebo-controlled cross-over trial
    Medical condition: "Healthy volunteers" Influence of the product on exercise induced muscle damage, noticable in temporal strength loss and muscle soreness. The indication is as defined in the SmPC: Swelling and infl...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017825-21 Sponsor Protocol Number: EC09/081 Start Date*: 2012-11-19
    Sponsor Name:INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD
    Full Title: Prospective, randomised, double-blind study to evaluate the efficacy of treatment with melatonin in adult patients with severe sepsis or septic shock.
    Medical condition: Severe sepsis or septic shock.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001297-18 Sponsor Protocol Number: ALN-AAT-001 Start Date*: 2015-06-29
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending, and Multiple-Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN...
    Medical condition: ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001962-94 Sponsor Protocol Number: EC07/90306 Start Date*: 2008-07-02
    Sponsor Name:Marc Miratvilles
    Full Title: Efecto antiinflamatorio bronquial del tratamiento sustitutivo en pacientes con déficit de alfa-1 antitripsina
    Medical condition: El déficit de alfa-1-antitripsina (AAT) es una enfermedad hereditaria de expresión autosómica recesiva que se caracteriza por concentraciones anormalmente reducidas de AAT en sangre, lo que comport...
    Disease: Version SOC Term Classification Code Term Level
    9 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003078-41 Sponsor Protocol Number: MUC-2/16 Start Date*: 2018-11-23
    Sponsor Name:MUCOS Pharma CZ s.r.o.
    Full Title: Reduction of post-traumatic systemic inflammatory response by Phlogenzym® using total hip replacement as a model.
    Medical condition: Total hip replacement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005217-14 Sponsor Protocol Number: DCR-A1AT-202 Start Date*: 2022-03-09
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients with PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease
    Medical condition: PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003385-14 Sponsor Protocol Number: AROAAT2001 Start Date*: 2019-08-06
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficie...
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10001806 - Alpha-1 anti-trypsin deficiency 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005326-36 Sponsor Protocol Number: Kamada-AAT(inhaled)-007 Start Date*: 2009-11-02
    Sponsor Name:Kamada Limited
    Full Title: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin...
    Medical condition: Alpha-1 Antitrypsin deficiency in patients with emphysema.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000342-12 Sponsor Protocol Number: VIO16EPI07-01 Start Date*: 2008-03-07
    Sponsor Name:Axcan Pharma Inc.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE SAFETY AND EFFICACY OF VIOKASE® 16 FOR THE CORRECTION OF STEATORRHEA IN PATIENTS WITH EXOCRINE P...
    Medical condition: Correction of steatorrhea (malabsorption of dietary fats) in patients with exocrine pancreatic insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000963-15 Sponsor Protocol Number: MATCH0.1 Start Date*: 2016-01-19
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH)
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001362-41 Sponsor Protocol Number: ALN-AAT02-001 Start Date*: 2018-12-03
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-...
    Medical condition: ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000917-59 Sponsor Protocol Number: ARCAAT2001 Start Date*: 2016-06-29
    Sponsor Name:Arrowhead Pharmaceuticals, Inc
    Full Title: An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as evidenced by changes in liver biop...
    Medical condition: Alpha-1 Antitrypsin Deficiency related liver disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003313-35 Sponsor Protocol Number: DCR-A1AT-201 Start Date*: 2022-01-18
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 ...
    Medical condition: PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) NL (Ongoing) PT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FR (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001309-95 Sponsor Protocol Number: MPH966-2-01 Start Date*: 2018-11-30
    Sponsor Name:Mereo BioPharma 4 Ltd
    Full Title: A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 wee...
    Medical condition: Alpha-1 antitrypsin deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DK (Completed) ES (Ongoing) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000068-86 Sponsor Protocol Number: AROAAT2002 Start Date*: 2019-07-01
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010335-41 Sponsor Protocol Number: RRK3728 Start Date*: 2009-06-30
    Sponsor Name:University of Birmingham
    Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    14.1 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003459-12 Sponsor Protocol Number: CE1226_4001 Start Date*: 2006-01-30
    Sponsor Name:CSL Behring GmbH
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly ...
    Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) FI (Completed) EE (Completed) SE (Completed) CZ (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-002402-36 Sponsor Protocol Number: IMP 11815/Amend.01/Amend.2 Start Date*: 2006-04-18
    Sponsor Name:Talecris Biotherapeutics
    Full Title: Multi-center, open-label trial to evaluate the safety and tolerability of Alpha-1 MP in subjects with Alpha-1-antitrypsin (α1AT) deficiency. STAMP: Safety and Tolerability of Alpha-1 MP
    Medical condition: Alpha-1 Antitrypsin (AAT) deficiency
    Disease: Version SOC Term Classification Code Term Level
    9 10001806 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:55:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA